ViWipe

Cervical cancer claims the lives of 342,000 women every year with 99% of cases linked to STIs, yet more than half of women under 35 avoid screenings due to fear and embarrassment. To lower barriers, ViWipe explores the medical potential of menstrual blood and applies advanced biotech to a simple, intuitive format inspired by daily toilet paper use. ViWipe is a paper-based, non-invasive self-test for menstrual blood collection and detection of STIs such as HPV, Chlamydia, and Gonorrhoea. Our technology relies on a multi-layered paper-based system that absorbs menstrual fluid in a single wipe. Samples are mailed and stored without the need for a cold chain. Molecular-based methods have been developed to detect the pathogens of interest using proprietary technology, and results can be delivered within an hour. With a cost under 5 pounds per test, ViWipe offers a scalable and accessible solution for women's reproductive health. ViWipe introduces a new menstrual blood collection format compatible with modular bioprocessing systems. Multiple patent-pending innovations ensure technical robustness and ease of use. Its non-invasive design empowers menstruating individuals with accurate, dignified tools for early screening, advancing national women's health goals by expanding access and reframing menstrual care as preventive care. Red Dot Award: Design Concept | Red Dot: Next Gen Award | Concept | Medical Devices and Technology